Markets· August 16, 2026 at 03:03 p.m.
AbbVie's Neuroscience Portfolio Projected to Generate $12.7 Billion in Revenue by 2026
Key takeaways
- AbbVie's neuroscience portfolio is projected to generate $12.7 billion in revenue by 2026
- The fastest-growing part of AbbVie's neuroscience business is migraine
- Therapeutic Botox remains one of the most durable assets in AbbVie's portfolio
AbbVie, a pharmaceutical giant known for its immunology products like Humira and newer blockbusters Skyrizi and Rinvoq, is seeing significant growth in its neuroscience division. The company's neuroscience portfolio, which generated $10.8 billion last year, is projected to reach approximately $12.7 billion in revenue during 2026. This growth is driven by various products including Vraylar for schizophrenia and bipolar disorder, therapeutic Botox, migraine drugs Ubrelvy and Qulipta, and Parkinson's disease therapy Vyalev.
